The multiple organizations supporting this initiative, including Oncopole, will contribute a total of $6.5 million to the Montreal Cancer Consortium over the next two years. As the project catalyst, TFRI is providing $2 million.
The MCC researchers will pursue their work toward improving treatments for cancer patients through precision and personalized medicine.
The MCC comprises many institutions: the Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM), the Goodman Cancer Research Centre (GCRC), the Centre de Recherche de l’Hôpital Maisonneuve-Rosemont (CR-HMR), the Institute for Research in Immunology and Cancer (IRIC), the Jewish General Hospital (JGH), McGill University, the Université de Montréal, Génome Québec Innovation Centre, and the Research Institute of the McGill University Health Centre (RI-MUHC).
More specifically, Oncopole supports the following project:
Inter-institutional coordination and integration of clinical data and biospecimens from patients treated through the Montreal Cancer Consortium.
This project is set to create and integrate harmonized tissue biobanking throughout the various MCC institutions. In this pilot project, priority will be given to cancers that benefit significantly from immunotherapy as a therapeutic approach while ensuring that biobanks meet registration and certification criteria. Tissues collected must also help meet the needs of other MCC projects.
This project will also enable all MCC members to use the ATiM, a Biobank Information Management System (BIMS) from the Canadian Tissue Repository Network (http://www.ctrnet.ca/resources/atim).
For this project, the consortium will count on the proven expertise of the following partners: the Cancer Research Network (RRCancer), the Canadian Tissue Repository Network (CTRNet) and Exactis Innovation (Exactis).
The Montreal Cancer Consortium is codirect by Ian Watson from the Goodman Cancer Research and John Stagg from the CHUM Research Center